TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33046214
Drug: Alternative lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative lipid-lowering treatments (PCSK9, LDLR, NPC1L1, APOC3, LPL)
Study: 37460410
Drug: Tobramycin inhalation
Normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tobramycin inhalation solution (TIS)
Study: 616869714
Drug: Treatment Satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Satisfaction (TIP)
Study: 35466498
Drug: Bar group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar group: overdentures connected to implants with bar/clip attachments
Study: 35466498
Drug: Telescopic group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telescopic group: overdentures connected to implants using a resilient telescopic attachment
Study: 35466498
Drug: Stud group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stud group: overdentures connected to implants with resilient stud (Locator) attachments
Study: 32145701
Drug: Flunixin meglumine
Normalized name: Flunixin Meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunixin meglumine (FM) 500 mg IV alone
Study: 36495036
Drug: CSPCHA115 (25-1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 (25-1000 mg) in SAD study
Study: 36495036
Drug: CSPCHA115 (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 (100, 200, 400, or 600 mg) in MAD study
Study: 36495036
Drug: CSPCHA115 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSPCHA115 (single and multiple doses)
Study: 33751764
Drug: Guided dose
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided dose reduction (GDR) - patients reduce no more than 25% of their baseline antipsychotic dose, with a 6-month stabilization period before further reduction.
Study: 33751764
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment group (MTG1) - patients continue their current antipsychotic treatment without reduction.
Study: 33751764
Drug: Naturalistic maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturalistic maintenance controls (MTG2) - eligible patients who do not intend to reduce antipsychotics.
Study: 32921569
Drug: Pain medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain medication (used by 166 out of 299 patients)
Study: 32546384
Drug: 15 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 minutes titration of intravenous oxytocin post birth
Study: 32546384
Drug: 30 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 minutes titration of intravenous oxytocin post birth
Study: 32546384
Drug: 60 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 minutes titration of intravenous oxytocin post birth
Study: 38371194
Drug: Osimertinib (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib (80 mg once daily)
Study: 33531075
Drug: Guadecitabine +
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine + GVAX (granulocyte macrophage‐colony‐stimulating‐factor secreting colon cancer vaccine)
Study: 34270379
Drug: Calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium gluconate (10%, 10 ml in 200 ml of physiologic saline, administered daily for four days starting on the day of ovum pickup)
Study: 35701842
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioral therapy for insomnia (CBT‐i) for 6 weeks, using Sleepio, an online interactive program with six sessions, once a week.
Study: 35701842
Drug: Digital cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital cognitive behavioral therapy for insomnia (CBT‐i)
Study: 38258369
Drug: Belimumab 1
Normalized name: belimumab 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belimumab 1 mg/kg
Study: 33230059
Drug: famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (20 mg bid)
Study: 33230059
Drug: omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole (20 mg qd)
Study: 34569408
Drug: Treatment escalation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment escalation studies
Study: 38573708
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg daily
Study: 34491340
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for T2DM plus training in diaphragmatic breathing and systematic relaxation for 6 months
Study: 34491340
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment for T2DM
Study: 33002131
Drug: Standard anticoagulants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anticoagulants
Study: 32453913
Drug: Febuxostat (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (120 mg for 4 days)
Study: 32453913
Drug: Allopurinol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (300 mg for 7 days)
Study: 32487102
Drug: Erenumab (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab (monthly for 6 months)
Study: 36397217
Drug: Acupuncture+rTMS combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture+rTMS combination group
Study: 33632189
Drug: Rhomboid intercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhomboid intercostal block (RIB) with 20-mL 0.375% ropivacaine
Study: 33632189
Drug: Rhomboid intercostal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhomboid intercostal block with sub-serratus plane block (RISS) using a total of 40-mL 0.375% ropivacaine
Study: 33837571
Drug: PMS50 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMS50 supplementation (550 mg/day)
Study: 35164698
Drug: Home-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based exercise training (n=20), 40 min/session, at least 4 times/week for 12 weeks, with protein supplementation (9 g/day).
Study: 35164698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n=20), received exercise instruction without active encouragement and continuous monitoring, with protein supplementation (9 g/day).
Study: 36114133
Drug: Optimal nonpharmacologic
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal nonpharmacologic therapy (Control)
Study: 33559439
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with ibuprofen sustained‐release capsule
Study: 33559439
Drug: Ibuprofen sustained‐release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen sustained‐release capsule
Study: 32568651
Drug: 220 mg
Normalized name: urea 220 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 220 mg of intravenous theophylline
Study: 35292925
Drug: Bumetanide (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (oral liquid formulation 0.5 mg bid)
Study: 39115709
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy
Study: 32719263
Drug: Extraoral approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraoral approach of GNB with 4 mL of 0.5% bupivacaine and 40 mg of triamcinolonacetonide
Study: 32719263
Drug: Intraoral approach
Normalized name: ALCOHOL 80 mL in 100 mL INTRADURAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoral approach of GNB with 4 mL of 0.5% bupivacaine and 40 mg of triamcinolonacetonide
Study: 34302609
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone spray + oral betamethasone (0.1 mg/kg per day for 7 days)
Study: 34302609
Drug: Intranasal beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal beclomethasone spray only
Study: 33392871
Drug: SAMSON trial
Normalized name: Samson 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAMSON trial - three-arm-N-of-1 trial for patient nonadherence to statin therapy
Study: 34988975
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% 5-fluorouracil (5-FU)
Study: 34988975
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% imiquimod (IMIQ)
Study: 33555418
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin (rosuvastatin 20 mg daily × 14 days)
Study: 33555418
Drug: Control (rosuvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (rosuvastatin 5 mg daily × 14 days)
Study: 32830164
Drug: AWL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWL with no treatment
Study: 35746502
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine separate administration group
Study: 35746502
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (simultaneous and separate administration)
Study: 39080153
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice daily
Study: 36345026
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRHa)
Study: 34391418
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days of glucocorticoid treatment
Study: 34391418
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of glucocorticoid treatment
Study: 35144636
Drug: Fenofibrate therapy
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenofibrate therapy (n=2673)
Study: 32958718
Drug: Early favipiravir
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early favipiravir therapy (starting on day 1)
Study: 32958718
Drug: Late favipiravir
Normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Late favipiravir therapy (starting on day 6)
Study: 33813328
Drug: Osimertinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib plus carboplatin-pemetrexed combination therapy
Study: 35685899
Drug: basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: basic treatment
Study: 33367744
Drug: Fulacimstat 25
Normalized name: Fulacimstat
DrugBank: Fulacimstat (DB15085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulacimstat 25 mg twice daily
Study: 34763534
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure at five specific acupressure points (1 min/point, twice a day for 4 weeks)
Study: 34763534
Drug: Non-specific acupressure
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-specific acupressure at five non-specific acupressure points (1 min/point, twice a day for 4 weeks)
Study: 36474344
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily for 30 days
Study: 33303457
Drug: Intranasal Ketodex
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketodex (combination of dexmedetomidine and ketamine)
Study: 38285446
Drug: Intravenous ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketamine
Study: 33303457
Drug: Intranasal Ketodex
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal Ketodex
Study: 33058991
Drug: Liberal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal oxygen therapy
Study: 35956400
Drug: Curcumin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1.5 g/day)
Study: 34465809
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of rhKAL to vascular smooth muscle cells
Study: 38191245
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment
Study: 34901039
Drug: RD1 group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD1 group (15 ml of 0.375% ropivacaine plus 0.5 μg/kg DEX with 0.1 mg/kg dexamethasone)
Study: 33764851
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g soy protein
Study: 36399131
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy
Study: 34975829
Drug: Egg Oral
Normalized name: Egg Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg Oral Immunotherapy (OIT)
Study: 33171557
Drug: Real-time navigation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Real-time navigation guided implant insertion
Study: 33171557
Drug: Free-hand implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free-hand implant insertion
Study: 33171557
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with length <47.5 mm
Study: 33171557
Drug: Implants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants with length ≥47.5 mm
Study: 33171557
Drug: Proximal implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proximal implant group
Study: 33171557
Drug: Distal implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal implant group
Study: 37261907
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP)
Study: 33798287
Drug: Misoprostol treatment
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol treatment
Study: 32119135
Drug: Lidocaine infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion (2 mg/kg before anesthesia induction and 2 mg/kg/hr during anesthesia)
Study: 38459552
Drug: Levonorgestrel implant
Normalized name: levonorgestrel IMPLANT KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel implant
Study: 33899743
Drug: ‐40 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: ‐40 mm Hg INP treatment
Study: 36266601
Drug: CTT augmented
Normalized name: CTT-1057
DrugBank: CTT-1057 (DB14965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTT augmented with Ologen implant
Study: 94013260
Drug: Active/passive immunization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active/passive immunization (combination of active and passive immunization)
Study: 94013260
Drug: Passive immunization
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive immunization with hepatitis A immunoglobulin preparation Globuman
Study: 94013260
Drug: Active immunization
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active immunization with inactivated hepatitis A vaccine Epaxal Berna (measured with IMX test)
Study: 35986234
Drug: butylphthalide group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: butylphthalide group: 0.2 g of butylphthalide capsules three times daily plus routine treatment (aspirin 50-300 mg/d, clopidogrel 75 mg/d, etc.)
Study: 35986234
Drug: control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group: routine treatment (aspirin 50-300 mg/d, clopidogrel 75 mg/d, etc.)
Study: 33766761
Drug: Anti-hyperglycemic drugs
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hyperglycemic drugs combined with metformin (specific drugs not detailed)
Study: 33766761
Drug: Treatment regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment regimen effects on emotional distress
Study: 33181890
Drug: Adjunctive eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive eslicarbazepine acetate (ESL) 10–30 mg/kg/day; maximum 1200 mg/day
Study: 32801102
Drug: Adjunctive eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive eslicarbazepine acetate (ESL)
Study: 38218919
Drug: Sham laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham laser treatment
Study: 33577946
Drug: Goals aligned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goals aligned with clinician treatment goals
Study: 37161534
Drug: Simvastatin treatment
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin treatment
Study: 32197640
Drug: Tongmai Yangxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tongmai Yangxin pill (TMYX)
Study: 32648985
Drug: Cernitin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cernitin (4 capsules/day)
Study: 32648985
Drug: Tadalafil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (5 mg/d)
Study: 35868341
Drug: Twice-daily dolutegravir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dolutegravir with rifampicin
Study: 35868341
Drug: Twice-daily dolutegravir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dolutegravir
Study: 35969360
Drug: Gefapixant 45
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 45 mg
Study: 36273162
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy via teleconference (5 weekly sessions)
Study: 36087590
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 14 days
Study: 36301961
Drug: B-vitamin/folate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamin/folate therapy (folic acid, vitamins B12, B6)
Study: 36301961
Drug: B-vitamin/folate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamin/folate therapy (folic acid, vitamin B12)
Study: 36301961
Drug: B-vitamin/folate therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-vitamin/folate therapy (vitamin B6)
Study: 34454599
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment before alveolar bone grafting
Study: 34454599
Drug: No orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No orthodontic treatment
Study: 36328358
Drug: GLPG1205 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLPG1205 100 mg
Study: 36017744
Drug: Warfarin (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (additional 18-month treatment)
Study: 36017744
Drug: Placebo (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (additional 18-month treatment)
Study: 33909759
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy (guidance, therapeutic techniques, airway protection maneuvers, orofacial myofunctional and vocal exercises, diet introduction)
Study: 33444934
Drug: risperidone +
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: risperidone + fish oil (FO) (EPA 740 mg and DHA 400 mg daily)
Study: 32495933
Drug: TBA ≥
Normalized name: Tribromoacetaldehydehydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: TBA ≥ 40.00 μmol/L
Study: 32332459
Drug: Lurasidone 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 240 mg/d
Study: 34854748
Drug: Optilume® drug-coated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optilume® drug-coated balloon (DCB)
Study: 34474301
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of natalizumab (4-week intervals)
Study: 33077341
Drug: Peg–IFN–α2a 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg–IFN–α2a 180 μg
Study: 33077341
Drug: Ropeginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon alfa‐2b 270 μg
Study: 33077341
Drug: Ropeginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon alfa‐2b 360 μg
Study: 33077341
Drug: Ropeginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon alfa‐2b 450 μg
Study: 35673948
Drug: Phenobarbitone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone (20 mg/kg) followed by Levetiracetam
Study: 36482794
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content (VLNC; 0.4 mg/g; n = 29)
Study: 36482794
Drug: Normal nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal nicotine content (NNC; 15.8 mg/g; n = 31)
Study: 33594488
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Insulin
Study: 33594488
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Insulin
Study: 36006603
Drug: Wearable fitness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wearable fitness trackers used for 12 weeks during CBT treatment
Study: 34621497
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing Therapy (EMDR)
Study: 34621497
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Writing Therapy (CBWT)
Study: 33423318
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (budesonide 400 μg/day)
Study: 33423318
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of budesonide with oral statin (simvastatin 10 mg/day)